GlassScriptPhysician profile
Andrew Michael Gross
NPI 1942341334
$2,756.95
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $668 · 2020: $557 · 2021: $567 · 2022: $690 · 2023: $275.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $275.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biodelivery Sciences International, INC. | $413.50 | 2019-2021 | |
| Abbvie INC. | $353.21 | 2021-2023 | |
| Scilex Pharmaceuticals INC. | $341.70 | 2020-2023 | Ztlido |
| Nevro Corp. | $332.55 | 2019-2022 | |
| Amgen INC. | $300.74 | 2019-2022 | |
| Allergan, INC. | $226.71 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $161.20 | 2020-2023 | Belbuca |
| Stimwave Technologies Incorporated | $113.33 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $89.03 | 2022 | |
| Medtronic, INC. | $77.48 | 2022-2023 | Intellis Adaptivestim |
| Boston Scientific Corporation | $65.65 | 2019-2023 | Superion Indirect Decompression System |
| Triad Life Sciences INC. | $53.50 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $34.69 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $30.34 | 2019-2021 | |
| Si-Bone, INC. | $29.24 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Depuy Synthes Sales INC. | $24.59 | 2022 | |
| Daiichi Sankyo INC. | $24.36 | 2019 | |
| Pacira Therapeutics, INC. | $20.07 | 2020 | |
| Horizon Therapeutics Plc | $19.12 | 2022 | |
| Pfizer INC. | $16.72 | 2023 | |
| Novartis Pharmaceuticals Corporation | $16.44 | 2020 | |
| Currax Pharmaceuticals LLC | $12.78 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Gross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.